clinical trial · NCT07064486
A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia
BrightGene Bio-Medical Technology Co., Ltd.·phase3·active not recruiting·n = 152
Type 2 Diabetes (T2DM)BGM0504BGM0504Semaglutide
brief summary
This trial is conducted in Indonesia. The aim of the trial is to evaluate the efficacy and safety of BGM0504 versus semaglutide as add-on to metformin in patients with type 2 diabetes
started
Jul 4, 2025
primary completion
Apr 30, 2027
completion
Apr 30, 2027
last updated
Oct 13, 2026
official title
A Phase 3, Randomized, Open Label Trial Comparing Efficacy and Safety of BGM0504 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol